The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
Abstract
The National Cancer Institute (NCI) Extramural IL2/LAK Working Group treated 93 patients with 114 cycles of high-dose intravenous (IV) interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells in three phase II trials. Thirty-six patients had metastatic melanoma, 35 had metastatic renal cell cancer, and 22 had colorectal cancer. All patients had a Karnofsky performance status greater than or equal to 80% and normal laboratory tests and organ function, and had received no more than one prior form of immunotherapy or chemotherapy. Objective responders were eligible to receive up to two additional courses of therapy at 12-week intervals. The most frequent toxicities were a capillary leak syndrome resulting in marked extravascular fluid shifts, and hypotension requiring treatment with large volumes of IV fluids and vasopressor agents. Laboratory and clinical evidence of hepatic and renal dysfunction were virtually universal. Intensive care-level support was routinely provided and the toxicity observations confirmed the need for this level of care. The life-threatening toxicities were cardiac and pulmonary. Five of the 27 patients who experienced significant respiratory compromise required intubation and mechanical ventilatory support. Twenty patients developed cardiac arrhythmias, the majority of which were supraventricular. There was a single episode of ventricular tachycardia requiring cardioversion. Four patients had transient cardiac ischemia, and an additional four had myocardial infarctions, one of which was fatal. With these exceptions, all toxicities were rapidly reversible. The occurrence of only a single therapy-related death and a very low incidence of other irreversible or life-threatening events is comparable to the level of toxicities often observed in other phase II trials. Although the intensity of this regimen limits this approach to a subset of cancer patients with excellent performance status and adequate organ function, because of the frequency and apparent durability of complete responses, this treatment warrants further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161501 · Cited by 2,735
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
Mulé, J. J., Shu, S., Schwarz, S. L., & Rosenberg, S. A. (1984) · Science · doi:10.1126/science.6332379 · Cited by 688
Lotze, M. T., Matory, Y. L., Ettinghausen, S. E., Rayner, A. A., Sharrow, S. O., Seipp, C. A. Y., Custer, M. C., & Rosenberg, S. A. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.4.2865 · Cited by 613
Self-citationLafrenière, R., & Rosenberg, S. A. (1985) · PubMed · Cited by 380
Clinical effects and toxicity of interleukin-2 in patients with cancer
Lotze, M. T., Matory, Y. L., Rayner, A. A., Ettinghausen, S. E., Vetto, J. T., Seipp, C. A., & Rosenberg, S. A. (1986) · Cancer · doi:10.1002/1097-0142(19861215)58:12<2764::aid-cncr2820581235>3.0.co;2-z · Cited by 355
Self-citationDutcher, J. P., Creekmore, S., Weiss, G. R., Margolin, K., Markowitz, A. B., Roper, M., Parkinson, D., Ciobanu, N., Fisher, R. I., & Boldt, D. H. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.477 · Cited by 235
Self-citationMier, J. W., Vachino, G., van der Meer, J. W. M., Numerof, R. P., Adams, S., Cannon, J. G., Bernheim, H. A., Atkins, M. B., Parkinson, D. R., & Dinarello, C. A. (1988) · Journal of Clinical Immunology · doi:10.1007/bf00916947 · Cited by 212
Self-citationNew Approaches to the Immunotherapy of Cancer Using Interleukin-2
ROSENBERG, S. A., LOTZE, M. T., & MULÉ, J. J. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-6-853 · Cited by 205
Cited by
Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.688 · Cited by 1,391
Self-citationMcDermott, D. F., Regan, M. M., Clark, J. I., Flaherty, L. E., Weiss, G. R., Logan, T. F., Kirkwood, J. M., Gordon, M. S., Sosman, J. A., Ernstoff, M. S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.206 · Cited by 820
Self-citationWarrell, R. P., de The, H., Wang, Z.-Y., & Degos, L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290307 · Cited by 776
The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia
Frankel, S. R., Eardley, A., Lauwers, G., Weiss, M., & Warrell, R. P. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-292 · Cited by 705
Siegel, J. P., & Puri, R. K. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.694 · Cited by 465
Cardiotoxicity of Cancer Therapy
Floyd, J. D., Nguyen, D. T., Lobins, R. L., Bashir, Q., Doll, D. C., & Perry, M. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.789 · Cited by 372
Robertson, M. J., Soiffer, R. J., Wolf, S. F., Manley, T. J., Donahue, C., Young, D., Herrmann, S. H., & Ritz, J. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.3.779 · Cited by 354
Vascular leak syndrome: a side effect of immunotherapy
Baluna, R., & Vitetta, E. S. (1997) · Immunopharmacology · doi:10.1016/s0162-3109(97)00041-6 · Cited by 280
Caligiuri, M. A., Murray, C., Robertson, M. J., Wang, E., Cochran, K., Cameron, C., Schow, P., Ross, M. E., Klumpp, T. R., & Soiffer, R. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116161 · Cited by 269
Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities
Roybal, K. T., & Lim, W. A. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052302 · Cited by 124
Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin 2
Citterio, G., Pellegatta, F., Lucca, G., Fragasso, G., Scaglietti, U., Pini, D., Fortis, C., Tresoldi, M., & Rugarli, C. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.533 · Cited by 18
Metadata
- Authors
- Margolin, K. A., Rayner, A. A., Hawkins, M. J., Atkins, M. B., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Doroshow, J. H., Jaffe, H. S., & Roper, M.
- Venue
- Journal of Clinical Oncology
- Published
- 1989-04
- Volume
- 7
- Issue
- 4
- Pages
- 486-498
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1904436785
- Cited by
- 346
- References
- 15
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.